| Schedule of disaggregation of revenues |
Our disaggregated revenues were as follows (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended
September 30, | | Nine Months Ended
September 30, | | | 2022 | | 2021 | | 2022 | | 2021 | | Royalties | | $ | 99,551 | | | $ | 58,563 | | | $ | 254,496 | | | $ | 141,264 | | | | | | | | | | | | Product sales, net: | | | | | | | | | | Sales of bulk rHuPH20 | | $ | 19,259 | | | $ | 18,862 | | | $ | 60,764 | | | $ | 59,719 | | | Sales of proprietary products | | 24,180 | | | 6,185 | | | 44,559 | | | 17,454 | | | Sales of device partnered products | | 17,988 | | | — | | | 24,544 | | | — | | | Total product sales, net | | $ | 61,427 | | | $ | 25,047 | | | $ | 129,867 | | | $ | 77,173 | | | | | | | | | | | | Revenues under collaborative agreements: | | | | | | | | | | Upfront license and target nomination fees | | $ | — | | | $ | 2,000 | | | $ | 30,000 | | | $ | 42,000 | | | Event-based development and regulatory milestones and other fees | | 44,000 | | | — | | | 59,000 | | | 30,000 | | | Sales-based milestones | | — | | | 30,000 | | | — | | | 50,000 | | | Device Licensing and development revenue | | 3,998 | | | 220 | | | 5,257 | | | 870 | | | Total revenues under collaborative agreements | | $ | 47,998 | | | $ | 32,220 | | | $ | 94,257 | | | $ | 122,870 | | | | | | | | | | | | Total revenue | | $ | 208,976 | | | $ | 115,830 | | | $ | 478,620 | | | $ | 341,307 | |
|
| Schedule of accounts receivable, deferred revenues from contracts with customers, and amounts under collaborative agreements included in transaction price |
Accounts receivable, net, and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands): | | | | | | | | | | | | | | | | | September 30, 2022 | | December 31, 2021 | | Accounts receivable, net | | $ | 164,135 | | | $ | 90,975 | | | Contract assets | | 69,167 | | | — | | | Deferred revenues | | 6,419 | | | 4,276 | | | | | | |
|